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Abstract—Prescription of conflicting concurrent medications,
polypharmacy, is recognised as a significant problem in the
UK, but its extent is not fully known. We combined a process
mining approach with text analytics, to discover prescription
processes for patients from five primary care sites in the UKWest
Midlands. Free-text prescription instructions were combined with
online knowledge about drug interactions to reveal that almost
62% of patients were prescribed with medication with some
level of interaction, during a two year period. We describe a
novel domain-specific approach to reduce the complexity of the
mined processes, which will nevertheless be applicable to other
flexible environments such as knowledge work. We also highlight
difficulties encountered in accessing, interpreting and processing
the data, which may be significantly mitigated through wider
adoption of a mindset of curating data for automated analysis.
Index Terms—Process mining, text analysis, polypharmacy,
health informatics, big data, web scraping.
I. INTRODUCTION
Polypharmacy refers to the concurrent prescription of mul-
tiple medications for a single patient [18], [22]. It is a growing
problem [5], in particular due to increasing numbers of patients
suffering from multiple chronic diseases (multimorbidity),
arising from factors including ageing populations and im-
proved treatment of chronic disease [46]. The increased burden
of treatment is a particular concern for those with multimor-
bidity as they frequently take many medications related to each
individual condition. Polypharmacy has the potential to reduce
treatment adherence [34], [58], and is associated with negative
health outcomes such as cognitive impairment [31] or hospital
stays due to adverse drug events [36]. These negative outcomes
are most evident amongst the elderly [57], [44] where they are
compounded by the drug-drug interactions found when three
or more sets of clinical guidance are combined [14]. When not
carefully monitored and regularly reviewed, polypharmacy can
result in adverse interactions between a patient’s medications,
reducing their effectiveness or causing additional problems.
These problems are recognised in the UK, but their extent is
not fully known.
Prescribing occurs as part of following the care pathway (or
process) for treating a patient for a particular condition, and
polypharmacy is just one of the problems that can occur in
following several such pathways concurrently. Understanding
these processes would give insight into the root causes leading
to problems and enable effective improvements to be put
into place. We are formally modelling care pathways using
process notations [60], in order to detect and resolve conflicts
including between medication, lifestyle recommendations and
scheduling. Such resolutions have the potential to improve
the effectiveness and efficiency of pathways, reduce the cost
and patient burden from unnecessary medication and resultant
complications, and improve patient experience.
Process mining [51] enables the discovery and analysis of
processes, such as those found in service industries [48] or
healthcare [32], [41], from data. We describe a pilot study
using process mining principles and text analytics to analyse
the drug prescription aspect of care processes, using prescrip-
tion data from primary care sites in the UK West Midlands
region, to gain insight into the prevalence of polypharmacy.
In this study we focus only on patients with six common
chronic conditions1; there will be a much greater extent of
interactions and polypharmacy across UK primary care as a
whole. We ask two main questions: firstly, which conflicting
drugs are prescribed together, how often, and how severe
are any potential interactions? Secondly, what frequently-
occurring patterns of prescription can be identified to give
insight into the underlying causes of polypharmacy and enable
mitigations to be developed? More details of the clinical
rationale can be found in the study protocol [5].
Process mining was developed to discover and analyse a
business’ processes using ‘event data’ routinely recorded by
its information systems. It has been successfully applied in
healthcare [32], [41], e.g. to model hospital workflows [38].
While many graph mining methods exist for learning patterns
of connections and causal relationships between entities [56],
process mining can account for activities occurring in parallel
(concurrency) and with non-zero duration, both of which are
crucial for our analysis. We conduct our analysis with a
process mining mindset, considering the medication that a
1Chronic Obstructive Pulmonary Disease (COPD), Coronary Heart Disease
(CHD), Hypertension, Osteoarthritis, Type 2 Diabetes and Depression.
patient takes as an ‘activity’ occurring over a period of time,
prescriptions as ‘events’ indicating the start of an activity, and
asking questions about the amount and type of concurrency
and how the pattern of prescriptions (process) evolves over
time. Mining complex, noisy and low-structured processes is
an active area of process mining research, to which this work
may contribute.
In Section II we introduce process mining and how it applies
to the analysis of prescription data. We then describe (Section
III) our data analysis process to investigate the polypharmacy
question. We focus on text processing to transform unstruc-
tured clinical records into suitable data for process mining;
a process mining, generalisation and visualisation approach
appropriate for the medication prescription data; and obtaining
initial results on polypharmacy (Section IV). We found that
almost 62% of patients in our sample received medication with
some level of interaction, which our clinical study [5] will
explore in more detail. We provide initial analysis in Section
V, and briefly discuss some of the problems we encountered in
obtaining and processing the data, which could be significantly
mitigated by relatively simple changes and adopting a mindset
of curating data for the purposes of automated analysis. The
final section (VII) outlines future research to integrate the
analysis into the wider question of discovering and resolving
conflicts between care pathways, and to extend the process
mining ideas to flexible and noisy processes more generally.
II. PROCESS MINING APPROACH
Process mining [51] uses ‘event’ data routinely collated by
an organisation’s computer systems to learn models of its
business processes, and to represent and reason about them
both visually and formally. It is related to data mining but
distinguished by considering the process as a whole. A similar
methodological approach is often needed, i.e. select and pre-
process data, carry out mining, and interpret the results [40].
Typical data mining techniques seek to identify relationships
between variables statically (association rule mining), over
time series (e.g. trends), or find patterns over sequences of
measurements (sequential or structural pattern mining). Pro-
cess mining in contrast explicitly considers whole processes
and the activities involved, especially the relationships (causal,
concurrent, cyclical or mutually exclusive) between them. A
recent hybrid approach, Local Process Mining [47], applies
similar methods to discover frequent process fragments, con-
ceptually closer to sequence mining. Further aspects include
comparing processes, modelling resource usage or perfor-
mance, or discovering logical inconsistencies in the process.
Whereas the goal of data mining is often predictions of the
future states or trends, process mining initially focusses on
modelling and visualising the current state of the process.
Data mining concepts may then be employed alongside human
interpretation, for subsequent processing such as clustering or
prediction of process outcomes.
Defining criteria of process mining are the expectation
that activities may take time, be concurrent (overlap in time)
[53], data and processes may be complex or ‘noisy’ [21],
[61], and may be of interest from several viewpoints (e.g.
causal relationships, organisational structures, or ‘resources’).
Since we are interested in the interaction between concurrent
medication, defined by the events of prescription, and patterns
of prescription that may lead to such interactions, process
mining seems an appropriate approach to this analysis.
A process mining algorithm requires a minimum of three
pieces of information to be recorded for each event:
(1) An activity ID specifies what activity took place, which
might be receipt of an invoice or repair made. We use
the name of the medication prescribed.
(2) A case ID links related activities, e.g. for a particular
invoice or fault call. Patient IDs serve this purpose in our
analysis since we are interested in relations between all
medications prescribed to each patient.
(3) A timestamp specifies when the activity occurred, ideally
at a high level of granularity. We have the date the
prescription was issued.
From ‘traces’ (sequences) of these events a process discovery
algorithm attempts to infer so-called ‘dependency relations’
between activities, and thus a process model showing the
patterns in which activities can occur, i.e. in sequence, parallel,
mutually exclusive, or cyclically. Models have been repre-
sented in various languages such as Petri nets [54], but the
use of Business Process Model and Notation (BPMN) [37] is
becoming a de facto standard. Following discovery, models
can be analysed for conformance to (similarity with) other
processes or business rules [43], [3], [13], performance or
bottlenecks [2], [52], interaction between resources [7], or to
predict outcomes or simulate process changes [55], [39], [27].
Although many process mining techniques require these
three pieces of data for an event, other approaches try to
determine a process from less [16], while many use additional
data to ether improve discovery, e.g. using both activity start
and end times [9], [28], or to ‘enrich’ the process model. For
example a clinical process might be enhanced with clinician
names, results of tests or GP comments, especially any com-
ments relating to shared decision making with the patient.
Process mining has been successfully used in secondary
care [41], [32], [38], but to the best of our knowledge not
to investigate patterns of medical prescription. We view the
sequence of prescribing medications to patients as a type of
process. A typical business process, for example for processing
an invoice, has a defined start and end point (receipt and
payment of the invoice), and a model of the process defines
the possible sequences of activities. The steps taken for a
particular invoice describe one process ‘case’. Our situation
differs in that the start and end point of each case (a single
patient) is artificially imposed by the data extract. However, we
face similar challenges: concurrency, ‘noisy’ and diverse data
(many medications and feasible combinations), and complex
models within which we want to find the most frequent
behaviour. We consider each prescription of a medication as
an ‘activity’ taking place for a given time, associated with
start (issuing the prescription) and end (completing the course)
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Fig. 1: Data processing pipeline for analysis of prescription data for polypharmacy.
events. Different medication may be prescribed sequentially,
concurrently (polypharmacy) or as alternative paths through
the process (e.g. for treating different conditions).
A particular problem faced in process mining in healthcare
contexts is that processes tend to be complex and dynamic,
involve multiple disciplines or departments, and may be ad-
hoc [40], [29], allowing many variants. Process discovery then
results in so-called ‘spaghetti’ models [50], [15] – too complex
to interpret or visualise. Numerous approaches to manage
such models have been proposed, from focussing on the
most-followed activities and paths [21], [28], to pre-clustering
process traces [40], [17], [6], to semantic interpretation of
activity names [11], [35]. It is, however, still an open problem,
with no universally-applicable solutions. The most appropri-
ate approaches may be data- or application-dependent. We
propose a representation appropriate for the prescription data,
which represents concurrency (between multiple medications)
implicitly.
III. DATA ANALYSIS
In the next sections we describe the steps taken to obtain,
clean and process prescriptions and interactions data into a
form suitable for the analysis. The process is summarised
in Fig. 1. We broadly follow what is becoming the standard
approach to process mining projects; obtain and pre-process
log files, carry out control-flow process discovery, further
analysis, and report results [8], [40]2.
A. Data specification and extraction
Five primary care sites (General Practitioner (GP) surgeries)
were selected, having a variety of demographic characteristics
(Table I). Each site has a PC running Windows XP and the
Egton Medical Information Systems (EMIS) Web3 application
and database providing access to real-time patient data and
care process management. A custom report4 was used to
extract prescription data covering a period of just over 2 years
(27 months, from 2 Dec 2014 to 28 Feb 2017), for patients
diagnosed with at least one of the six major chronic diseases
chosen. Data were extracted for between 515 and 2,940
2Code at https://bitbucket.org/uobmitcon/ichi2018/.
3https://www.emishealth.com/products/emis-web/.
4Report and data extract by PRIMIS http://www.nottingham.ac.uk/primis/.
Raw Event Log Processed Data
Site Patients Prescriptions Patients Prescriptions
Bo 515 36,940 507 29,064
Ma 1,259 158,953 1,238 126,851
QB 1,343 125,441 1,339 107,786
EH 2,541 268,696 2,502 215,243
KN 2,940 208,557 2,895 160,694
Total 8,598 798,587 8,481 639,638
TABLE I: Prescription data extracted from five sites, showing patient
counts and number of prescriptions in the source data, and after pre-
processing to extract prescription end dates where feasible.
patients per site (8,598 in total), 36,940–268,696 prescriptions
(total 798,587). Ethical approval was granted for this work
by the University of Birmingham Research Ethics Committee,
with reference number ERN_16-0074.
Each record details the issuing of a prescription for a
single medication to a patient. In four cases the extract was
formatted as an Excel spreadsheet; in the final case the PC was
underpowered and the extract was made to HTML and post-
processed. The final output was converted to comma-separated
(CSV) format for subsequent processing. The fields extracted
are listed in Table II. The data includes pseudonymised patient
identifiers, demographics (gender and age at date of extract),
date of issuing the prescription, structured text specifying the
medication, quantity, and free text from the GP to the patient
specifying the amount of medication and prescription regimen.
Data were also extracted to enable future analysis by the
demographics of the practice and by medical condition, but
are not the subject of the analysis described in this paper.
B. Determine Prescription End Dates
To assess polypharmacy, we require knowledge of when
prescriptions were made, and either how long a medication
was being taken by a patient, or prescription end dates. The
latter can be inferred in many cases from four key fields listed
in Table II: (1) Name, Dose and Quantity (NDQ), (2) Dose,
(3) Quantity, (4) Quantity Unit.
‘NDQ’ is relatively structured and includes medication name
and information such as tablet size (e.g. ‘Metformin
850mg tablets’, ‘Aciclovir 5% cream’).
Field(s) Example Fields Description
Demographics QB, e777ab. . ., Male, 67,
EH, 945ba6. . ., Female, 51,
Site code, anonymised patient ID, gender and age (18–104).
Date of Issue 11-Feb-15 Date the prescription was issued to the patient.
Name, Dosage and Quantity
(NDQ)
‘Metformin 850mg tablets’
‘Zerobase 11% cream (Thornton & Ross Ltd)’
Medication name and details (structured).
Dose ‘Take one three times a day for a week’
‘To be taken as directed’
GP instructions to the patient (unstructured).
Quantity 168 Number of tablets supplied, volume of liquid, etc.
Quantity Unit tablet Tablet, gram, unit, etc.
EH, 6ce8921. . ., Female, 68, 03-Aug-16, ‘Metformin 850mg tablets’, ‘Two Tablets Daily At The Same Time Each Day’, 56, tablet
EH, cbac5a6. . ., Male, 75, 30-Dec-16, ‘Zerobase 11% cream (Thornton & Ross Ltd)’, ‘use as moisturiser as often as necessary’, 500, gram
TABLE II: Summary of the data fields extracted, and two example records.
‘Dose’ is the critical field, containing free-text notes from the
GP specifying how much medication is prescribed, when
and how it should be taken, and how often.
‘Quantity’ indicates how much medication was prescribed
(number of tablets or volume), and
‘Quantity Unit’ specifies the method of delivery from about
30 options including ‘tablet’, ‘ml’, ‘spray’, ‘syringe’.
Although ‘Dose’ is free text, there is some limited structure,
perhaps due to the constrained domain (prescribing) and the
EMIS Web application remembering previously-entered data.
Thus we can construct a grammar to parse many of the entries
for the required information.
We infer prescription end dates using a sequence of data
cleaning and parsing as follows, to extract the quantity of
medication to be taken per dose, and frequency, from which
to infer the number of days the medication will last, and thus
the end date.
1) Data Cleaning (Pre-processing): Before parsing, data
cleaning was necessary due to the unstructured format of
the ‘Dose’ field in particular, data missing by design or
inappropriate for automated processing, and for simplification
for further processing:
(1) Free-text entry leads to typographical errors and inconsis-
tent use of grammar such as plurals. These were identified
and corrected. We also removed text redundant for the
task at hand, such as GP instructions (e.g. ‘dissolve the
contents of’, ‘for subcutaneous injection’).
(2) In almost 9% of cases it is impossible to determine the
amount of medication used, and hence the end date: med-
ication specified with a non-specific dose (‘emollient’,
‘shampoo’ and similar); ‘Quantity Unit’ such as ‘device’
or ‘spray’ without specification of the size of the device
or amount of medication delivered; and prescriptions with
vague instructions, especially all variations of ‘use as
directed’. These were all excluded, together with records
with data errors such as unexpectedly empty fields, or
basic data problems such as non-numeric quantities.
These records were excluded from subsequent processing.
(3) Text such as ‘into both eyes’, ‘in each nostril’ was
used to determine a multiplier to simplify the final dose
calculation.
2) Text Processing to Obtain End Dates: A grammar was
developed to parse the unstructured ‘Dose’ to extract quantity
and time information5. The basic form of the field is
Dose ::- <directive> <quantity> <unit>
<frequency> <time-spec>
as seen in the examples in Table II. These main elements
can however be combined in the data in many ways to
convey similar information (‘take one tablet daily’ vs ‘one
tablet to be taken each morning’), some may be omitted (‘1
tablet mane’) or other information included (‘one tablet daily
with food’). We combine several sub-grammars for processing
broad categories of medication which differ in general format,
e.g. according to prescription by volume (liquids), by discrete
unit (e.g. tablets) or other (syringes) as identified by the
‘Quantity Unit’ field.
In outline the parser recognises numeric values as digits,
fractions, words or ranges; time specifications given numer-
ically, using clinical abbreviations (‘o.d.’, ‘mane’) or collo-
quially (‘every morning’, ‘with evening meal’); and amounts
given numerically or approximately (‘half a mil’, ‘1 tea-
spoon’). These are converted to a numeric quantity of medi-
cation per dose (e.g. number of tablets or volume of liquid)
and frequency, from which a nominal amount of medication,
possibly fractional, per day is calculated. This is combined
with the ‘Quantity’ field to give the duration of the prescription
and hence the end date. The more structured ‘NDQ’ field
provides additional information, e.g. the volume per dose of
medication administered by syringe.
In the first example in Table II, 56 tablets were prescribed
on 3 Aug 2016, ‘Two Tablets Daily At The Same Time Each
5Grammar implemented using the Python pyparsing module.
Day’, so 2 tablets per day last for 28 days, thus ending on
31 Aug 2016. No end date can however be inferred from the
second example, since it is not known how much moisturiser
will be consumed per use, nor how often will be necessary,
so this record is excluded.
3) Remarks on the Learning Process: Since this is a real-
world dataset not created with automated processing in mind,
there is no ground truth which we can use to quantify the
precision or recall of the grammar against known training or
test corpora. Instead, qualitative assessment by experts was
used to iteratively refine the grammar to identify the main
text structures, test, refine to account for un-parsed records,
repeating until the returns in reduced exclusion rate no longer
justified the effort. (Future work could perhaps attempt to
create simulated data sets faithful to the observed data, but
these are likely to be overly noise-free, leading to artificially
positive evaluations of learning accuracy.)
We made various assumptions in interpreting the data, prin-
cipally to err in the direction of over-reporting polypharmacy
rather than risk omitting dangerous combinations of drugs.
Unclear dose or time specifications were simplified where pos-
sible to the value leading to the longest period of prescription
(e.g. ‘one or two’ tablets becomes ‘one’). Similarly, complex
specifications such as ‘every night for 2 weeks then twice a
week for 3 months’ were reduced to the first time specification
(assuming the rate of prescription reduces). Fixed-term time
specifications (actual dates) were ignored, and alternating
dose specifications such as ‘20mg/40mg alternate days’ were
simplified to the first. These and other limitations, including
‘outlier’ text structures outside the scope of the grammar,
could be resolved with additional development effort. Just
under 20% of the extracted records were removed as not
processable by the pre-processing (9%) and grammar (11%).
C. Inferring Medication Conflicts
Medication conflicts are sourced from an online presentation
of the British National Formulary (BNF)6. The BNF lists
details of medications, and ‘standard’ and ‘strong’ interactions
between individual and groups of medications7. We store the
interacting drugs as nodes in a graph database, creating two
relations: standard and strong interactions. Further relations
define groups of drugs, to record interactions inherited from
the group, and to map commercial to generic drug names. This
mapping is found at a different section of the website and is
necessary because the prescription data refers to drugs using
a mix of both generic and commercial names.
Graph databases provide appropriate mechanisms to record
a chain of relationships between two drugs:
{commercial name
synonym
−−−−→ generic name
belongs to
−−−−−→
medication group
interacts with
←−−−−−−→ medication group
belongs to
←−−−−− generic name
synonym
←−−−− commercial name}.
6BNF (https://www.bnf.org/) data was ‘scraped’ from https://bnf.nice.org.
uk/ using the Python lxml.etreemodule html. Data was stored in a Neo4j
(https://neo4j.com/) graph database accessed using the py2neo module.
7The most recent BNF allows for four levels of interaction.
A commercial name (e.g. ‘Nurofen’) may be a synonym for a
generic name (‘ibuprofen’) and perhaps a member of a group
of drugs (‘non-steroidal anti-inflammatory drugs’) which in-
teract with another group (‘corticosteroids’). A member of
the latter group (‘betamethasone valerate’) may also have a
commercial instantiation (‘Betnovate’). Medication may be
specified as, and interactions require identification between,
various of these links, e.g. ‘Nurofen’ prescribed with ‘anti-
inflammatory drugs’, or ‘ibuprofen’ with ‘Betnovate’. The
database query language enables such chains to be retrieved,
stored and queried efficiently so that the interactions can be
captured at whichever level they are specified.
We retrieved lists of drugs from two pages of the BNF,
firstly associating commercial with generic drug names, sec-
ondly linking to the interactions. These lists were inconsis-
tent, necessitating basic text pre-processing: to match plurals,
name variants (‘Hepatitis A vaccine’/‘Hepatitis vaccines’) and
remove chemical specifiers (‘hydroxide’, ‘acetate’, etc.). We
also reduce detailed commercial drug names to their basic
format as used in the prescription data, e.g. ‘Alecensa 150mg
capsules (Roche Products Ltd)’ becomes ‘Alecensa’).
In total 2,360 drug names (generic and commercial) were
extracted, 927 group relationships, 5,770 standard and 5,151
strong interactions, and 1,232 commercial drug names. Query-
ing the database to identify all unique interactions accounting
for name synonyms and groups results in 148,567 standard,
61,113 strong interactions.
D. Process Mining
As described in Section II, we take a process mining
approach to interpret the prescriptions data. The ‘activity’
that a patient is prescribed a medication occurs over a time
frame (between ‘Date of Issue’ and the inferred end date),
and multiple such ‘activities’ may overlap wholly or partially
(polypharmacy). Our present interest is to detect such overlaps
to analyse the prevalence of drug interactions, but a natural
extension is to identify frequent patterns of prescription and
understand the underlying causes. Therefore we build ‘process
models’ of the patterns of prescription, which may be inter-
preted formally and visually, and from these obtain the data
necessary for later statistical analysis.
1) Standard Process Mining: We first carried out an ex-
ploratory analysis of the prescription data using existing
process mining algorithms (Alpha [53], Heuristics Miner [61]
and Inductive Miner [28]) and tools (ProM8, Disco9 and
Apromore10). Process mining requires as a minimum the first
three data fields shown in Table III together with the mappings
from our data. We additionally provide the inferred end dates
to enable activity durations to be taken into account. We found
that the data was too heterogeneous to produce visually useful
models, producing classically ‘spaghetti’ visualisations [50],
[15]. While there exists much literature on dealing with this
problem, including separating multiple processes entangled in
8http://www.promtools.org/.
9https://fluxicon.com/products/.
10http://apromore.org/.
Required
Field
Mapped Data
Field
Process Mining Description
Case ID Patient ID Entity involved, typically
invoice or fault number, etc.
Event ID Drug Name Steps involved in the process.
Start Time Date of Issue Start time of the activity.
End Time Inferred End Date Activity end time.
TABLE III: Minimal fields for process mining. We regard a single
patient as a ‘case’, and the medications prescribed as the ‘activities’
in the process, indicated by the ‘events’ of their prescription. Note
that end times are not required by many process mining algorithms,
but are critical for our analysis.
the data (e.g. [20], [40], [17], [6]), and focusing on the most
frequent process patterns to produce manageable models [61],
[21], [28], these raise questions over interpretation and the
validity of the complexity-reducing decisions which are made.
Therefore we took a bespoke approach, described next.
2) Domain-Specific Complexity Reduction: To restrict the
complexity of the models resulting from process mining in a
manner which is faithful to the data domain and the questions
we investigate, we made two simplifying decisions:
(1) concentrate on per-patient models, and
(2) model concurrency implicitly, by merging concurrent
medication into single medication groups.
The first decision allows for simpler process models to
be produced while still collecting statistics on frequency of
medication interactions. The models allow visualisation of
basic patterns of prescription, and the method provides a
basis for domain-specific generalisation (Section III-D4) and
future analysis of patterns of prescription across the whole
patient cohort in a principled manner. The second decision
is driven by the fact that the entity of interest is groups of
medication prescribed at any one time, rather than the times
when individual drugs are prescribed or completed. Therefore
we aggregate concurrency into the nodes in our process maps,
representing a unique group of concurrent medication in each
node (Fig. 2). Each time a prescription is started or completed,
this group changes, and a new node is created and linked
appropriately. In this way there is no concurrency between
nodes in the model, which we represent as a type of finite state
machine and annotate with frequency, duration and interaction
information. Per-patient statistics on polypharmacy interaction
can be simply extracted from these models.
3) Domain-Specific Process Mining: We mine a ‘prescrip-
tion process’ for each patient:
(1) Extract and simplify medication names from ‘NDQ’
(remove information on tablet size etc.) to reduce the
granularity of activity names.
(2) Sort ‘Date of Issue’ and ‘End Date’ from each record
into an ordered list of start/end prescription events. On
clinician advice, we assume that no prescription lasts less
than one day, multiple contiguous prescriptions of the
same medication (re-issues) should be merged, and mul-
tiple simultaneous prescriptions (e.g. multiple boxes of
tablets) of the same drug should be treated as sequential.
(3) Build a Probabilistic Prefix Tree Automaton (PPTA) [10]
from this consolidated sequence of events. For a single
patient, this is simply a sequence of nodes representing
groups of concurrent drugs (Fig. 2(a), connected by arcs
when the group changes. Adding multiple patients into
the same structure produces a tree labelled with frequency
of change between the nodes.
(4) Naïvely construct a Probabilistic Deterministic Finite
Automaton (PDFA) [10], [59] from the PPTA, where no
state (group of medications) is repeated. The PPTA is
parsed depth-first from the start node, noting the groups
of medications represented by each node. When a node
n is encountered representing a group M of medications
already seen in node n′, the target of its unique input arc
(n) and source of any output arcs are connected instead to
n
′, resulting in a reduced, connected, model with cycles
(Fig. 2(b)). Depending on the pattern of prescription for a
patient, the PDFA may be little different from the PPTA
(e.g. very varied groups of concurrent medications), or
much more similar to a traditional process model, with a
defined start and end node, showing a pattern of regular
prescription (Fig. 2(b). Although the PDFA is labelled
from the data with frequencies with which each node
and arc is passed, treating it as probabilistic allows for
future generalisation and analysis using methods from the
automata and regular language learning literature (e.g.
[10], [23]), e.g. for frequent patterns of prescription.
The resulting models are annotated for standard and strong
interactions, and duration of prescription, from which we
obtain statistics for analysing polypharmacy, summarised in
Table IV. Fig. 2(b) shows a relatively compact example of a
‘prescription process’ for a single patient, consolidated from
a long sequence of prescription combinations (Fig. 2(a)), sug-
gesting a relatively structured prescription process. Standard
(orange) and strong (red) interactions are highlighted. The
process is entered at the top, at the start of the time period
for which the data was collected, and exited at the double-
bordered (green) box which shows the prescription at the end
of the time period. The weights of nodes and arcs give some
indication of how much time was spent in each node, and how
often each arc was traversed. The dotted box indicates that
there were frequently gaps when no medication was prescribed
– although this may reflect data problems such as mismatch
between the date a prescription was issued and actually taken.
4) Domain-Specific Generalisation and Analysis: We ap-
ply methods to generalise, or reduce the complexity of the
model, in a manner which is sympathetic to the domain. At
present these methods are purely heuristic. Less significant
nodes (short-duration and small groups of medication) are
absorbed into their neighbours (Fig. 3(a)), according to some
thresholds, then strongly-overlapping neighbours (parent-child
and sibling nodes) merged (Fig. 3(b). Iteratively, this will
reduce a complex model to a very simple one – ultimately
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Fig. 2: (a) Sequence of prescription events for a single patient,
(b) mined ‘prescription process’ PDFA. Nodes represent a group of
concurrently-prescribed medications, annotated with the number of
times the combination occurred (in brackets) and total days duration
(‘130d’) Arcs have zero duration. Yellow (red) orange text indicates
standard (strong) interactions. The topmost node shows the drugs
prescribed at the start of the extract period; the double-bordered
(green) node those at the end (reached by following the arcs).
to be part of an interactive tool to allow clinicians to control
the useful level of generalisation.
We plan to develop more rigorous approaches to generalisa-
tion using metrics to measure the divergence in behaviour from
that recorded in the event (prescription) log as nodes and arcs
are removed or consolidated. This is the practice with other
process representations (e.g. [21], [43]) but will be adapted
to our probabilistic models and effect of grouping medication,
and closely related to generalising probabilistic automata [23].
IV. POLYPHARMACY RESULTS
We outline here the initial findings drawn from the data
analysis. An initially surprisingly high prevalence of polyphar-
macy is revealed. In total there were one or more interactions
for almost 62% of the patients (approximately 54% with
drugs with standard, 38% with strong interactions). These
represent up to 50 and 16 unique combinations of standard-
and strongly-interacting drugs respectively per patient. Overall
there were 2,672 distinct pairs of drugs prescribed having a
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Fig. 3: Example of domain-specific generalisation, for the prescrip-
tion process shown in Fig. 2(b): (a) after merging short-duration
and small-group nodes into their neighbours; (b) after also merging
neighbouring nodes representing similar groups of medications; and
(c) after repeated merging with reducing threshold of similarity
between groups.
standard interaction, 784 with a strong interaction. Although
these figures seem very large, there are clinical reasons why
some level of interaction between drugs may be necessary and
accepted by clinicians – for instance, tolerance by the patient
and mitigation of a more serious problem or interaction.
Uncertainties such as interpreting the exact time when a
prescription begins may also be responsible. Table V lists the
top ten strongly-interacting drugs, by the number of patients
prescribed and by the mean duration of prescription. The top
pair, Simvastatin and Amlodipine, are treatments to reduce
cholesterol and treat high blood pressure, respectively, and
guidelines exist on dose limitations when taken together. This
suggests that further information is needed to understand the
true severity and impact of the interactions reported. We
hypothesize that this may in some cases be obtainable from
the prescription text, and also from expert knowledge.
Table IV reports the main summary statistics. The cleaned
data contained 1,076 different drugs prescribed to 8,481
patients, with almost 95,000 different groups of concurrent
medication prescribed. 639,638 prescription records were con-
solidated to about 250,000 by merging sequential and du-
plicate prescriptions (Section III-D). Individual patients were
prescribed with between 1 and 45 different drugs, via up to
Per-Patient Min. Max. Mean Total
Prescription Events 1 1,568 75.42 639,638
Consolidated Prescriptions 1 268 29.54 250,513
Unique Medications 1 45 7.68 1,076
Unique Prescriptions 1 209 14.84 94,735
Standard Interactions 0 1,643 36.67 310,958
Strong Interactions 0 819 12.65 107,255
Unique Standard Interactions 0 50 2.39 2,672
Unique Strong Interactions 0 16 0.81 784
TABLE IV: Summary statistics for polypharmacy analysis. ‘Min.’,
‘Max.’ and ‘Mean’ are calculated per patient (from 8,481 patients),
‘Total’ across the whole patient cohort.
Drug Patients Drug Drug Days Drug
amlodipine 355 simvastatin alfuzosin 192.00 felodipine
furosemide 227 ramipril alfuzosin 146.50 cardioplen xl
bendroflu-
-methiazide 226 ramipril adizem-xl 104.12 nebivolol
amlodipine 147 doxazosin adizem-xl 88.67 metoprolol
indapamide 135 ramipril citalopram 87.25 warfarin
citalopram 116 naproxen eprosartan 82.60 indapamide
clarithromycin 111 simvastatin methadone 80.75 olanzapine
amitriptyline 110 tramadol eplerenone 77.00 valsartan
amitriptyline 107 gabapentin bendroflu-
-methiazide 76.00 valsartan
indapamide 106 simvastatin haloperidol 63.58 valproic acid
TABLE V: The ten most frequent strong interactions identified, by
total number of patients prescribed (left) and mean duration (right).
1,568 (unconsolidated) prescriptions.
Fig. 4(a) shows that there is a ‘short tail’ of such very large
numbers of prescriptions in the data set (occurring for each
site). A similar profile is seen for the numbers of interactions.
However although the patient with the largest number of
prescriptions over the time period of the data extract also has
the largest number of interactions, the Pearson’s coefficient of
correlation of standard (strong) interactions with prescription
count is only 0.52 (0.46). (Each data series in Fig. 4(a) is
sorted independently.) In this case, the 1,568 prescriptions
reflect up to 31 prescriptions issued on 157 days. Further
investigation is needed to determine underlying reasons.
Figs. 4(b) and (c) confirm that there is some correlation
between the number of prescriptions for a patient and the
number of unique interactions (no duplicates), and between the
numbers of standard and strong interactions for a patient. A
fuller analysis of these results, including by site, demographics
and patient condition, will be published elsewhere.
V. DISCUSSION
The analysis showed the feasibility of applying a process
mining approach to this type of data, despite the concept of
a ‘prescription process’ being loosely defined and differing
from the usual conception of a process, for example having
a start and end point defined only by the parameters of the
data extract. The resulting models exhibit a variety of process-
like structures, and the initial polypharmacy results are of
great interest to begin to answer the questions raised by the
protocol [5]. Detailed analysis will now be carried out, to
relate polypharmacy to different patient cohorts, sites, clinical
conditions, and to investigate root causes.
Our aim in using a probabilistic representation is that
machine learning methods can be applied in a well-founded
manner. We hope to apply clustering and clique detection to
per-patient and multi-patient models, respectively, to discover
common patterns of prescription that will be informative for
clinicians in understanding the underlying reasons leading to
polypharmacy. Our initial explorations in this direction have
shown that such patterns are elusive, as hinted by the large
numbers of different prescription and interaction combina-
tions. We hope that again the involvement of clinician process
and medication experts will enable appropriate methods to be
developed and conclusions drawn.
Effective application of process mining and analysis of
resultant models in the context of ‘noisy’ data and processes
remains an open question. In fields with particularly heteroge-
neous data, flexible and variable processes such as healthcare,
and more generally ‘knowledge work’ and Adaptive Case
Management, naïve application of process mining algorithms
results in ‘spaghetti’ (impossibly complex) models. We sug-
gest that data-specific complexity-reduction and generalisation
methods have a place in controlling complexity in a manner
sympathetic to the domain in which process mining is applied.
Our approach was to deal with concurrency implicitly for both
mining and visualisation/generalisation. We plan to develop
this as a more general method for dealing with loosely-defined
(goal-oriented) processes.
Despite the useful results obtained from our method, and the
promise of ‘big data’ [33] in healthcare [30], [26] more gen-
erally to enable evidence-based improvements to healthcare,
we encountered considerable difficulties in gathering, clean-
ing, processing and interpreting data from multiple sources.
Many of these difficulties seem symptomatic of a fragmented
and evolving approach to data collection, presentation and
storage, and could be significantly mitigated by relatively
simple changes and adopting a mindset of curating data for
the purposes of automated analysis. This can be seen in three
main areas.
Firstly, text analytics allow information to be retrieved
from free text, but a relatively large proportion (20% of
records) could not be processed, potentially reducing the
accuracy of the results. These issues included data errors,
diminishing returns in modelling all nuances of the free text
language used, and vague or missing information (such as
the instruction to ‘take as directed’). Adopting a data and
system design strategy of curating data for automated analysis
would allow these exclusions to be significantly reduced and
enable other useful analyses to be conducted more effectively
in the future. Secondly, the availability of online information
on drug interactions facilitated our analysis, but was hampered
by frequent changes to the websites, partly due to evolving
clinical information, but also again due to a lack of design
for automated analysis. An adoption of the expectation that
all data will be used (and useful) for automated analysis, stan-
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Fig. 4: Summary per-patient statistics on prescriptions: (a) scaled counts of prescriptions (before and after consolidation), standard and strong
interactions, (b) counts of interactions against prescriptions, (c) some correlation (Pearson=0.63) between standard and strong interactions.
dardisation of formats and control of data revision processes,
and consistency of naming conventions, would all improve
the accuracy and efficiency of the analysis. Finally, clearly
defined data semantics is also crucial. For example, at the
process mining stage we assumed prescriptions to start on
the ‘Date of Issue’, but this could be inaccurate, increasing
the complexity of the mined models. Expert knowledge may
mitigate this, but clear data descriptions should be provided to
preserve data decisions and interpretations for future analyses.
VI. LIMITATIONS AND FUTURE WORK
This study developed organically out of a need to answer
particular questions from a given data set. As such it has
several limitations which we aim to address in future work.
Firstly, without a ground truth for the text analysis the eval-
uation of the grammar, although by experts, is necessarily
subjective. The insights gained through this analysis would
enable generation of hand-annotated or simulated data sets.
Careful consideration will be necessary to ensure these are
not overly-optimistic of the quality of data generated.
Secondly, a quality metric is required to measure and
compare the generated process models, to enable well-founded
generalisation. Since concurrency is implicit in the nodes,
the present approaches to merging nodes to reduce visual
complexity increase the concurrency, which may not be valid.
Automata learning theory [10], [23] suggests starting points
for such metrics [59]. At present, clinical experts are evalu-
ating the medical conflicts retrieved, and will also guide the
development of the model representation and a tool to support
interactive visualisation of results. This assessment will be
formalised and brought into the wider context of detecting
and resolving conflicts between clinical pathways [60].
A limitation of the process mining techniques so far de-
veloped is the very large number of potential ‘activities’
(2,360 possible drugs, 1,076 seen in prescriptions). Even after
aggregation into nodes representing groups of drugs, we still
obtain ‘spaghetti’ models when mining models for multiple
patients’ prescriptions. Application to a wider set of condi-
tions, and also to secondary care will add further complexity,
not only in increased numbers of drugs and interactions, but
also due to different drug formularies. Process mining is a
visual technology, most usefully applied in close collaboration
between (in our case) clinical and process mining experts.
We plan to involve clinicians, pharmacists and other experts
in developing the most useful representations and visualisa-
tions. There may also be further domain-specific information
available from analysis of the GP comments, e.g. on shared
decision-making with the patient, which can be used to to
interpret the relevance of discovered polypharmacy and hence
potentially reduce complexity of the discovered processes.
Finally, additional data is needed to connect prescription
processes and drug interactions discovered, with changing
patient conditions. We hope to develop the analysis in this
way using longitudinal data on patient disease coding.
VII. CONCLUSION
Certain age groups and clusters of diseases place patients at
increased risk. Little is known of the effect of polypharmacy
and patterns of prescribing on multimorbid patients [49]. Our
initial analysis showed that almost 62% of patients in our
sample were prescribed drugs for which some form of inter-
action is known; strongly interacting for nearly 40%. Since
polypharmacy and difficulties in de-prescribing are widely
acknowledged [34], [58], [31], [14], this work and the further
analysis it enables have potentially enormous benefit for
healthcare providers, users and the wider healthcare economy.
We showed that process mining is a suitable approach
to identify the underlying prescription processes leading to
polypharmacy. Text and other data analytics tools enabled
data to be brought together and interpreted from a number of
sources, and shortcomings in data formats and documentation
to be, to an extent, circumvented. The full analysis will
facilitate a more tailored approach [24] relatable to groups
of patients or combinations of morbidities, to help support the
decision-making process of which drugs can be usefully de-
prescribed – there is evidence that patients want to reduce their
medication [19], [45], however previous attempts to reduce the
numbers of inappropriate prescriptions have failed [25].
We plan to integrate the analysis with our ongoing work
in detecting and resolving conflicts between care pathways
[60], to identify and use common patterns in prescription to
understand the root causes leading to polypharmacy, and to
recommend process changes to reduce its effect and improve
the efficiency of prescribing and patient experience. We also
plan to develop and apply the process mining approach for
wider application to loosely-defined, goal-oriented processes.
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